AMAG PHARMACEUTICALS, INC. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Product sales, net
Service revenues, net
License fee, collaboration and other revenues
Total revenues
Revenues
Product sales, net
Collaboration revenue
Other revenues
Total revenues
Costs and expenses:
Cost of services
Cost of product sales
Research and development expenses
Acquired in-process research and development
Selling, general and administrative expenses
Acquisition-related costs
Impairment of assets
Restructuring expenses
Total costs and expenses
Operating loss
Other income (expense):
Interest expense
Loss on debt extinguishment
Interest and dividend income, net
Interest and dividend income
Other income (expense)
Total other income (expense)

Income (loss) before income taxes
Total other expense, net
Loss from continuing operations before income taxes
Income tax (benefit) expense
Net loss from continuing operations
Discontinued operations:
Income from discontinued operations
Gain on sale of CBR business
Income tax expense
Net income from discontinued operations
Net loss
Basic and diluted earnings per share:
(Loss) income from continuing operations (in dollars per share)
Income (loss) from discontinued operations (in dollars per share)
Total (in dollars per share)
(Loss) income from continuing operations (in dollars per share)
Income (loss) from discontinued operations (in dollars per share)
Total (in dollars per share)
Loss from continuing operations (in dollars per share)
Income from discontinued operations (in dollars per share)
Total (in dollars per share)
Weighted average shares outstanding used to compute earnings per share (basic and diluted) (in shares)
Diluted (in shares)

Comments